Ivabradin Stada (Ivabradine Hydrochloride)

Ivabradin Stada acts on the cardiac If current, making it useful in several heart‑related conditions.

• Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance by lowering heart rate.
• Heart failure with reduced ejection fraction: decreases hospitalization risk and enhances symptom control through heart‑rate reduction.
• Ischemic heart disease: helps control myocardial oxygen demand by maintaining a lower heart rate.
• Tachycardia associated with angina: provides rate control when beta‑blockers are insufficient or contraindicated.

• Ivabradine selectively blocks the funny (If) current in the sinoatrial node, slowing the spontaneous depolarisation of pacemaker cells. This results in a reduction of heart rate without affecting myocardial contractility, ventricular repolarisation, or systemic blood pressure, thereby decreasing cardiac oxygen demand.

Ivabradin Stada may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Visual disturbances (phosphenes): transient luminous phenomena, usually mild and reversible.
• Bradycardia: heart‑rate reduction below 50 beats/min in some patients.
• Headache: mild to moderate intensity, often transient.
• Dizziness: sensation of light‑headedness, especially on standing.

Serious or Rare Side Effects

• Symptomatic severe bradycardia: may cause fatigue, hypotension, or syncope.
• Atrial fibrillation: irregular rapid heart rhythm requiring medical evaluation.
• Persistent visual impairment: rare cases of lasting visual field changes.

Before prescribing Ivabradin Stada, clinicians should consider several safety precautions to minimize risk.

• Cardiovascular assessment: evaluate baseline heart rate and conduction system.
• Conduction disorders: avoid in patients with sick sinus syndrome or second‑degree AV block.
• Severe hepatic impairment: use with caution or avoid as metabolism is reduced.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Drug interactions: review concomitant medications that affect CYP3A4 or heart rate.
• Store below 25°C: keep in the original pack, protect from moisture.

Ivabradin Stada can interact with other medicines, influencing its plasma levels or additive heart‑rate effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase ivabradine exposure.
• Other bradycardic agents (beta‑blockers, digoxin, diltiazem): may cause excessive heart‑rate reduction.
• Concomitant use with other If channel blockers: risk of profound bradycardia.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may raise levels, dose adjustment may be needed.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Nitrates or other anti‑anginal drugs: monitor for additive effects on heart rate and blood pressure.